Genpharmasec Limited announced on November 3, 2026, that its Board of Directors has approved the sale of its entire equity stake in its wholly owned subsidiary, Clinigenome India Private Limited. The company stated that Clinigenome India Private Limited is not a material subsidiary. Upon completion of the sale, Clinigenome India Private Limited will cease to be a subsidiary. The expected completion date for this transaction is on or before March 31, 2027.
Board Approves Subsidiary Divestment
Genpharmasec Limited has announced a significant strategic decision following its Board of Directors meeting held on Tuesday, November 3, 2026. The Board has formally approved the disinvestment and sale of the company’s entire equity stake in its wholly owned subsidiary, Clinigenome India Private Limited.
Strategic Rationale and Impact
The company clarified that Clinigenome India Private Limited is not considered a material subsidiary. The divestment is expected to streamline Genpharmasec’s operations and portfolio. Upon the successful completion of this sale, Clinigenome India Private Limited will no longer be a subsidiary of Genpharmasec Limited. The details regarding the transaction, as required under Regulation 30 of the Listing Regulations, are provided in Annexure-A.
Financial Results and Leadership Changes
In addition to the divestment, the Board also considered and approved the Un-audited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2026, along with the Limited Review Report of the Statutory Auditor. The Board also approved the resignation of Mr. Hardik Makwana from his position as Company Secretary and Compliance Officer, effective from the close of business hours on November 16, 2026. Details for this resignation are provided in Annexure-B.
Transaction Details (Annexure-A)
The subsidiary, Clinigenome India Private Limited, contributed ₹100.47 Lakhs to Genpharmasec’s turnover in the last financial year, representing 0.72% of the consolidated turnover. Its net worth was reported as (₹154.41 Lakhs), which is 2.35% of the consolidated net worth. The agreement for sale is yet to be entered, and the company will intimate the exchanges upon signing. The expected completion date is on or before March 31, 2027, or another date approved by the Board. The consideration for the sale will be determined through negotiation and board approval. The proposed buyer identified is Micro Genomics India Private Limited. The transaction is not considered a related-party transaction and falls outside the Scheme of Arrangement.
Resignation Details (Annexure-B)
Mr. Hardik Makwana’s resignation is due to his pursuit of other professional opportunities outside the organization. His cessation is effective from November 16, 2026.
Source: BSE
